New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology

World Journal of Gastroenterology

Volumn 10, Issue 16, 2004, Pages 2327-2329

  Zhu, Xiao Dong ^a   Zhang, Wei Hua ^b   Li, Cheng Lin ^c   Xu, Yang ^b   Liang, Wei Jiang ^a   Tien, Po ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b Ciphergen Biosystems Inc   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; MALE; POPULATION RESEARCH; PREDICTION; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY; VIRUS CARRIER;

EID: 4344641407     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i16.2327     Document Type: Article

References (23)

1. Lai CL, Lok A, Wu PC, Ng M. Risk factors and hepatocellular cancer. Lancet 1985; 2: 329-330
2. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-680
3. Poniachik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little ME, Civantos F, Schiff ER. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996; 43: 568-571
4. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292: 587-592
5. He QY, Lau GK, Zhou Y, Yuen ST, Lin MC, Kong HF, Chiu JF. Serum biomarkers of hepatitis B virus infected liver inflammation: a proteomic study. Proteomics 2003; 3: 666-674
6. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486
7. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003; 3: 8-24
8. Xiang Y, Qian L, Wang B. Reversion of HBV-related liver fibrosis and early cirrhosis by baicao rougan capsule. Zhongguo Zhongxiyi Jiehe Zazhi 1999; 19: 709-711
9. Kozlowska J, Loch T, Jablonska J, Cianciara J. Biochemical markers of fibrosis in chronic hepatitis and liver cirrhosis of viral origin. Przegl Epidemiol 2001; 55: 451-458
10. Chang TT, Lin HC, Lee SD, Tsai YT, Lee FY, Jeng FS, Wu JC, Yeh PS, Lo KJ. Clinical significance of serum type-III procollagen aminopropeptide in hepatitis B virus-related liver diseases. Scand J Gastroenterol 1989; 24: 533-538
11. Luo R, Yang S, Xie J, Zhao Z, He Y, Yao J. Diagnostic value of five serum markers for liver fibrosis. Zhonghua Ganzangbing Zazhi 2001; 9: 148-150
12. Ding H, Chen Y, Feng X, Liu D, Wu A, Zhang L. Correlation between liver fibrosis stage and serum liver fibrosis markers in patients with chronic hepatitis B. Zhonghua Ganzangbing Zazhi 2001; 9: 78-80
13. Castera L, Hartmann DJ, Chapel F, Guettier C, Mall F, Lons T, Richardet JP, Grimbert S, Morassi O, Beaugrand M, Trinchet JC. Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J Hepatol 2000; 32: 412-418
14. Oh S, Afdhal NH. Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep 2001; 3: 12-18
15. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48: 1835-1843
16. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-3614
17. Banez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, McLeod DG, Moul JW, Srivastava S. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003; 170: 442-446
18. Adam BL, Vlahou A, Semmes OJ, Wright GL Jr. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 2001; 1: 1264-1270
19. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-577
20. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-1304
21. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF 3rd. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001; 17: 301-307
22. Coombes KR, Fritsche HA Jr, Clarke C, Chen JN, Baggerly KA, Morris JS, Xiao LC, Hung MC, Kuerer HM. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003; 49: 1615-1623
23. Xiao XY, Tang Y, Wei XP, He DC. A preliminary analysis of non-small cell lung cancer biomarkers in serum. Biomed Environ Sci 2003; 16: 140-148